Tiger Wound Care

Tiger Wound Care, founded in 2017, is a private, commercial-stage company operating in the biologics and regenerative medicine sector for wound care. It leverages its proprietary CAMPs (Cellular, Acellular, and Matrix-like Products) technology platform, derived from placental tissue, to develop and distribute a portfolio of shelf-stable allografts and wound dressings. The company is vertically integrated, controlling processes from donor recovery and tissue processing to distribution, and is currently conducting randomized controlled trials to further validate its technologies. Its business model is commercial, generating revenue from the sale of its approved wound care products.

CAMPs (Cellular, Acellular, and Matrix-like Products) technology leveraging processed human placental tissue (amnion and chorion) to create allografts that preserve extracellular matrix components and biological factors to support tissue repair and regeneration.

Tiger Wound Care operates in the highly competitive advanced wound care and regenerative medicine market. It competes directly with other companies offering placental tissue allografts (e.g., MiMedx, Human Regenerative Technologies, Skye Biologics) as well as broader wound care companies with biologic and synthetic matrices (e.g., Organogenesis, Integra LifeSciences, Smith & Nephew). Differentiation is based on processing methods, product claims, shelf life, clinical evidence, and price.